RCKT Latest Press Releases

-- October 15, 2026 --

Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference Business Wire 7:00 AM

-- October 7, 2026 --

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar Business Wire 9:36 AM

-- October 6, 2026 --

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital Business Wire 4:12 PM

-- September 15, 2026 --

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease Business Wire 7:00 AM

-- September 3, 2026 --

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire 7:00 AM

-- August 10, 2026 --

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress Business Wire 4:00 PM

-- August 3, 2026 --

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease Business Wire 7:00 AM

-- June 12, 2026 --

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million Business Wire 7:00 AM

Market Data Delayed 15 Minutes